

(51) International Patent Classification:
A01N 37/00 (2006.01)

(21) International Application Number:

PCT/US2011/026807

(22) International Filing Date:

2 March 2011 (02.03.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/309,816 2 March 2010 (02.03.2010) US

(71) Applicant (for all designated States except US): **IMA-GENETIX, INC.** [US/US]; 10845 Rancho Bernardo Road, Suite 105, San Diego, CA 92127 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **SPENCER, William** [US/US]; 10845 Rancho Bernardo Road, Suite 105, San Diego, CA 92127 (US). **HESSLINK, Robert, L., JR.** [US/US]; 10845 Rancho Bernardo Road, Suite 105, San Diego, CA 92127 (US).(74) Agent: **TAHMASSEBI, Sam, K.**; TechLaw LLP, 10755 Scripps Poway Parkway, Suite 465, San Diego, California 92131 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: COMPOSITIONS COMPRISING MYRISTIC ACID AND USES THEREOF

Anti-bacterial Efficacy of Myristic Acid on *P. gingivalis*

*n=3; VEHICLE: 5% ETHYLALCOHOL IN 3% METHYL BETA CYCLODEXTRIN IN SCHAEGLER'S BROTH (SB)

Figure 2

(57) Abstract: The teachings herein are directed to antibacterial and anti-inflammatory pharmaceutical compositions that include myristic acid. Further embodiments herein are directed to methods of administering sufficient amounts of myristic compositions to patients in need thereof in order to prevent or treat inflammation and/or bacterial infection. Myristic acid has been established to outperform other cetylated fatty acids in treating infection and inflammation, such as 1-TDC which includes cetylated myristic acid. The compositions and methods provided herein can further be used with additional anti-inflammatory, antibacterial, and delivery agents.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, **Published:**
GW, ML, MR, NE, SN, TD, TG).

— *with international search report (Art. 21(3))*